These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 37551557)

  • 1. Composite B-cell and T-cell lymphomas: clinical, pathological, and molecular features of three cases and literature review.
    Jin X; Liu H; Li J; Xiao X; Yuan X; Chen P; Chen B; Liang Y; Huang F
    J Zhejiang Univ Sci B; 2023 Aug; 24(8):711-722. PubMed ID: 37551557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Secondary cutaneous Epstein-Barr virus-associated diffuse large B-cell lymphoma in a patient with angioimmunoblastic T-cell lymphoma: a case report and review of literature.
    Yang QX; Pei XJ; Tian XY; Li Y; Li Z
    Diagn Pathol; 2012 Jan; 7():7. PubMed ID: 22260632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diffuse large B-cell lymphoma in patient after treatment of angioimmunoblastic T-cell lymphoma.
    Skugor ND; Perić Z; Vrhovac R; Radić-Kristo D; Kardum-Skelin I; Jaksić B
    Coll Antropol; 2010 Mar; 34(1):241-5. PubMed ID: 20432757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of rituximab on treatment outcomes of patients with angioimmunoblastic T-cell lymphoma; a population-based analysis.
    Meeuwes FO; Brink M; van der Poel MWM; Kersten MJ; Wondergem M; Mutsaers PGNJ; Böhmer L; Woei-A-Jin S; Visser O; Oostvogels R; Jansen PM; Diepstra A; Snijders TJF; Plattel WJ; Huls GA; Vermaat JSP; Nijland M
    Eur J Cancer; 2022 Nov; 176():100-109. PubMed ID: 36208568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Composite diffuse large B-cell lymphoma and CD20-positive peripheral T-cell lymphoma.
    Yamazaki S; Fujioka Y; Nakamura F; Ota S; Shinozaki A; Yamamoto G; Kamikubo Y; Nannya Y; Ichikawa M; Fukayama M; Kurokawa M
    Pathol Int; 2011 Nov; 61(11):662-6. PubMed ID: 22029677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Composite T lymphoblastic leukemia/lymphoma and diffuse large B-cell lymphoma: case report.
    Niino D; Ohsaki K; Arakawa F; Watanabe J; Kimura Y; Kiyasu J; Takeuchi M; Miyoshi H; Yoshida M; Sugita Y; Ohshima K; Okamura T
    Pathol Int; 2011 Jun; 61(6):363-8. PubMed ID: 21615612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting intratumoral B cells with rituximab in addition to CHOP in angioimmunoblastic T-cell lymphoma. A clinicobiological study of the GELA.
    Delfau-Larue MH; de Leval L; Joly B; Plonquet A; Challine D; Parrens M; Delmer A; Salles G; Morschhauser F; Delarue R; Brice P; Bouabdallah R; Casasnovas O; Tilly H; Gaulard P; Haioun C
    Haematologica; 2012 Oct; 97(10):1594-602. PubMed ID: 22371178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epstein-Barr virus (EBV) positive diffuse large B cell lymphoma of the elderly-experience of a single center from Turkey.
    Ozsan N; Cagirgan S; Saydam G; Gunes A; Hekimgil M
    Pathol Res Pract; 2013 Aug; 209(8):471-8. PubMed ID: 23726928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical characteristics and prognosis of patients with co-existing follicular lymphoma and diffuse large B-cell lymphoma components in rituximab era.
    Chen Y; Luo L; Chen L; Zheng X; Yang X; Zheng Z; Zheng J; Liu T; Yang T; Hu J
    J Cancer Res Clin Oncol; 2023 Jun; 149(6):2311-2318. PubMed ID: 36219261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First-line R-CVP versus R-CHOP induction immunochemotherapy for indolent lymphoma with rituximab maintenance. A multicentre, phase III randomized study by the Polish Lymphoma Research Group PLRG4.
    Walewski J; Paszkiewicz-Kozik E; Michalski W; Rymkiewicz G; Szpila T; Butrym A; Giza A; Zaucha JM; Kalinka-Warzocha E; Wieczorkiewicz A; Zimowska-Curyło D; Knopińska-Posłuszny W; Tyczyńska A; Romejko-Jarosińska J; Dąbrowska-Iwanicka A; Gruszecka B; Jamrozek-Jedlińska M; Borawska A; Hołda W; Porowska A; Romanowicz A; Hellmann A; Stella-Hołowiecka B; Deptała A; Jurczak W
    Br J Haematol; 2020 Mar; 188(6):898-906. PubMed ID: 31792945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epstein-Barr virus involvement is a predictive factor for the resistance to chemoradiotherapy of gastric diffuse large B-cell lymphoma.
    Yoshino T; Nakamura S; Matsuno Y; Ochiai A; Yokoi T; Kitadai Y; Suzumiya J; Tobinai K; Kobayashi Y; Oda I; Mera K; Ohtsu A; Ishikura S
    Cancer Sci; 2006 Feb; 97(2):163-6. PubMed ID: 16441428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 3A Comparison between R-THP-COP and R-CHOP Regimens for the Treatment of Diffuse Large B-cell Lymphoma in Old Patients: A Single-institution Analysis.
    Araie H; Sakamaki I; Matsuda Y; Tai K; Ikegaya S; Itoh K; Kishi S; Oiwa K; Okura M; Tasaki T; Hosono N; Ueda T; Yamauchi T
    Intern Med; 2017 Sep; 56(18):2407-2413. PubMed ID: 28824057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study.
    Xu-Monette ZY; Wu L; Visco C; Tai YC; Tzankov A; Liu WM; Montes-Moreno S; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Zhao XF; Choi WW; Zhao X; van Krieken JH; Huang Q; Huh J; Ai W; Ponzoni M; Ferreri AJ; Zhou F; Kahl BS; Winter JN; Xu W; Li J; Go RS; Li Y; Piris MA; Møller MB; Miranda RN; Abruzzo LV; Medeiros LJ; Young KH
    Blood; 2012 Nov; 120(19):3986-96. PubMed ID: 22955915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Severe Pancytopenia After COVID-19 Revealing a Case of Primary Bone Marrow Diffuse Large B Cell Lymphoma.
    Kilani Y; Sohail H; Lim CY; Payette A; Kamal SAF; Afzal A; Khan T; Paracha N; Muppidi MR; Sittler D
    Am J Case Rep; 2022 Sep; 23():e937500. PubMed ID: 36151707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical aspects of TP53 gene inactivation in diffuse large B-cell lymphoma.
    Voropaeva EN; Pospelova TI; Voevoda MI; Maksimov VN; Orlov YL; Seregina OB
    BMC Med Genomics; 2019 Mar; 12(Suppl 2):35. PubMed ID: 30871527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. c-MYC and p53 expression highlight starry-sky pattern as a favourable prognostic feature in R-CHOP-treated diffuse large B-cell lymphoma.
    Bouroumeau A; Bussot L; Bonnefoix T; Fournier C; Chapusot C; Casasnovas O; Martin L; McLeer A; Col E; David-Boudet L; Lefebvre C; Algrin C; Raskovalova T; Jacob MC; Vettier C; Chevalier S; Callanan MB; Gressin R; Emadali A; Sartelet H
    J Pathol Clin Res; 2021 Nov; 7(6):604-615. PubMed ID: 34374220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study.
    Dunleavy K; Fanale MA; Abramson JS; Noy A; Caimi PF; Pittaluga S; Parekh S; Lacasce A; Hayslip JW; Jagadeesh D; Nagpal S; Lechowicz MJ; Gaur R; Lucas A; Melani C; Roschewski M; Steinberg SM; Jaffe ES; Kahl B; Friedberg JW; Little RF; Bartlett NL; Wilson WH
    Lancet Haematol; 2018 Dec; 5(12):e609-e617. PubMed ID: 30501868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone Marrow Involvement of Epstein-Barr Virus-Positive Large B-Cell Lymphoma in a Patient with Angioimmunoblastic T-Cell Lymphoma.
    Lee T; Park BG; You E; Cho YU; Jang S; Lee SM; Suh C; Park CJ
    Ann Lab Med; 2018 Mar; 38(2):172-175. PubMed ID: 29214764
    [No Abstract]   [Full Text] [Related]  

  • 19. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
    Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
    Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pattern of failure and optimal treatment strategy for primary gastric diffuse large B-cell lymphoma treated with R-CHOP chemotherapy.
    Kang HJ; Lee HH; Jung SE; Park KS; O JH; Jeon YW; Choi BO; Cho SG
    PLoS One; 2020; 15(9):e0238807. PubMed ID: 32960887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.